ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Dec 5, 2012
FAQ: How Is Your Best Ideas Portfolio Doing This Year?
We answer a question that has come up a lot recently.
Dec 1, 2012
A Dual Focus on Valuation and Yield Is the Best Way to Combat Changes in Future Dividend Tax Rates
We think a dual focus on both valuation and high-yielders remains the best way to achieve portfolio income growth, while reducing the risk of permanent loss of capital from valuation missteps and exogenous events, namely potential changes in the dividend tax rate.
Sep 19, 2012
Microsoft Hikes Dividend, Signs Deal with RIM and More
Microsoft was in the headlines quite a bit Monday and Tuesday. Let's take a look at the recent newsflow of the dividend growth gem.
Jul 27, 2012
Merck Reports Solid Second Quarter; Its Drug Pipeline Looks Promising
Merck reported solid second quarter results and indicated that progress in its pipeline remains strong. Though the firm will face patent expiration of its blockbuster Singulair in coming weeks, we think shares remain fairly valued.
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry.
Mar 6, 2012
Merck Weighed Down by Currency But Reaffirms Full-Year 2012 Outlook
Merck said that first-quarter performance would be weighed down by currency, but the drugmaker reaffirmed its full-year 2012 results. We are maintaining our fair value estimate.
Jul 21, 2011
Merck's Shares Look Undervalued
We take a look at Merck's valuation.
Jul 11, 2011
Looking for a Pullback to Pick Up Johnson & Johnson's Shares
We think J&J's shares are fully-valued at this time, but we'd be looking to pick some up if the firm offered a dividend yield of 4%.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.